TherapyX, Inc. is advancing the development and commercialization of nanoencapsulated immune-modulatory biologics (NanoCapTM) for the treatment of autoimmune/inflammatory diseases, cancer and infection. The company’s Phase Inversion Nanoencapsulation (PIN) technology provides a customizable platform for the development of sustained-release nanoparticulate protein formulations. TherapyX, Inc. has a broad pipeline of products at discovery and pre-clinical stages. Our most advanced preclinical products are TGFβ NanoCapTM and IL12 NanoCapTM.
TherapyX Inc. has licensed the exclusive worldwide rights to the patented technology needed to produce sustained-release nanoparticulate protein therapeutics. The PIN technology represents a breakthrough in encapsulation of biological macromolecules for parenteral and oral delivery. In addition to maintaining full biological activity of the macromolecule, the process produces a drug product that sustains physiological levels of the therapeutic in the disease microenvironment and is shelf stable at room temperature. This unique formulation provides a significant advantage for TherapyX, Inc. over other competing generic biologics. The company is utilizing the PIN platform to expand its protein-based product pipeline via generation of human-like therapeutics with selective and predictable activity.